Characteristics | Category | Total | Female n (%) | Male n (%) | p value |
---|---|---|---|---|---|
Age | 14-19 | 333 | 233 (1.5) | 100 (1.5) | < 0.001 |
 | 20-29 | 3486 | 2866 (18.5) | 620 (9.1) |  |
 | 30-39 | 9774 | 6966 (45) | 2808 (41.2) |  |
 | 40-49 | 6292 | 4035 (26) | 2257 (33.1) |  |
 | 50+ | 2430 | 1392 (9) | 1038 (15.2) |  |
 | Total (n) | 22,315 | 15,492 | 6823 |  |
CD4 | < 50 | 3452 | 2173 (16.9) | 1279 (22.8) | < 0.001 |
 | 50-99 | 2942 | 1944 (15.1) | 998 (17.8) |  |
 | 100-149 | 3410 | 2391 (18.5) | 1019 (18.2) |  |
 | 150-249 | 5740 | 4152 (32.2) | 1588 (28.3) |  |
 | 250+ | 2954 | 2233 (17.3) | 721 (12.9) |  |
 | Total (n) | 18,498 | 12,893 | 5605 |  |
WHO Stage at antiretroviral therapy initiation | Stage 1 | 465 | 339 (3.4) | 126 (2.7) | < 0.001 |
 | Stage 2 | 7985 | 5615 (56) | 2370 (51.2) |  |
 | Stage 3 | 4982 | 3294 (32.9) | 1688 (36.5) |  |
 | Stage 4 | 1220 | 778 (7.8) | 442 (9.6) |  |
 | Total (n) | 14,652 | 10,026 | 4626 |  |
TB at antiretroviral therapy initiation | No | 21,207 | 14,847 (95.8) | 6360 (93.2) | < 0.001 |
 | Yes | 1108 | 645 (4.2) | 463 (6.8) |  |
 | Total (n) | 22,315 | 15492 | 6823 |  |
Sexually transmitted infection diagnosed at antiretroviral therapy initiation | No | 17,634 | 11,579 (74.7) | 6055 (88.7) | < 0.001 |
 | Yes | 4681 | 3913 (25.3) | 768 (11.3) |  |
 | Total (n) | 22,315 | 15,492 | 6823 |  |
Switch from first antiretroviral therapy | No | 20,675 | 14,313 (92.4) | 6362 (93.2) | 0.024 |
 | Yes | 1640 | 1179 (7.6) | 461 (6.8) |  |
 | Total (n) | 22,315 | 15,492 | 6823 |  |
Median months of follow-up time (interquartile range) | - | - | 32 (20-47) | 30 (18-39) | < 0.001 |